8,817 AbbVie Inc. $ABBV Shares Bought by Congress Asset Management Co.

Key Points

• Congress Asset Management Co. increased its AbbVie stake by 262.7% in the third quarter, purchasing 8,817 additional shares and bringing its holdings to 12,173 shares valued at approximately $3.18 million. Institutional investors collectively own 70.23% of AbbVie.
• AbbVie reported quarterly EPS of $3.65, beating estimates by $0.04, while revenue rose 10.2% year over year to $16.99 billion. The stock opened at $271.37, near its 12-month high of $274.94.
• AbbVie declared a quarterly dividend of $1.73 per share, equal to a 2.6% annualized yield, while analysts maintain a “Moderate Buy” consensus and an average price target of $274.32.

Congress Asset Management Co. raised its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 262.7% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,173 shares of the company's stock after purchasing an additional 8,817 shares during the period. Congress Asset Management Co.'s holdings in AbbVie were worth $3,184,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Corient Private Wealth LP bought a new position in AbbVie in the second quarter valued at approximately $559,736,000. Legal & General Group Plc bought a new stake in AbbVie during the second quarter worth $2,905,952,000. Jupiter Topco LLC bought a new stake in AbbVie during the second quarter worth $1,560,354,000. Cardano Risk Management B.V. boosted its holdings in shares of AbbVie by 914.6% in the 4th quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company's stock valued at $1,244,112,000 after purchasing an additional 4,908,260 shares in the last quarter. Finally, Diamant Asset Management Inc. increased its stake in shares of AbbVie by 21,649.0% in the 1st quarter. Diamant Asset Management Inc. now owns 3,671,231 shares of the company's stock valued at $798,456,000 after purchasing an additional 3,654,351 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the firm's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This trade represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.06% of the company's stock.

AbbVie Stock Up 1.8%

Shares of ABBV stock opened at $271.37 on Thursday. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $274.94. The stock's fifty day simple moving average is $258.27 and its 200 day simple moving average is $235.87. The firm has a market capitalization of $479.44 billion, a P/E ratio of 76.66, a P/E/G ratio of 1.22 and a beta of 0.24.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter last year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts expect that AbbVie Inc. will post 13.93 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie's dividend payout ratio (DPR) is currently 195.48%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The U.S. Food and Drug Administration granted two Breakthrough Therapy Designations to investigational telisotuzumab adizutecan (Temab-A/ABBV-400) for colorectal cancer and non-small cell lung cancer. The designations could accelerate development and regulatory review of the c-Met-directed antibody-drug conjugate, strengthening AbbVie’s oncology pipeline. AbbVie Temab-A Breakthrough Therapy Designations
• Positive Sentiment: AbbVie and Genmab reported that Epkinly (epcoritamab) plus R-CHOP reduced the risk of disease progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The Phase 3 result met its progression-free-survival goal and could support expanded use of Epkinly, potentially increasing its commercial opportunity and competitive position against Roche’s Polivy. AbbVie Epkinly Frontline DLBCL Results
• Positive Sentiment: Scotiabank raised its AbbVie price target to $320 from $280 and maintained a “sector outperform” rating, citing the company’s growth prospects. The higher target adds to bullish analyst sentiment following the oncology updates. Scotiabank Raises AbbVie Price Target
• Neutral Sentiment: AbbVie is scheduled to report third-quarter results later this month. Investors may look for evidence that newer products can offset long-term pressure from Humira and support the company’s full-year outlook. AbbVie Third-Quarter Earnings Preview
• Negative Sentiment: AbbVie narrowed its third-quarter 2026 EPS guidance to $3.73–$3.77, below the $3.85 analyst consensus cited in reports. Separately, commentary highlighted a reported payout ratio above 190%, raising questions about the sustainability of the dividend if earnings or cash flow weaken. AbbVie Third-Quarter Guidance

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. boosted their price target on AbbVie from $280.00 to $285.00 and gave the stock an "overweight" rating in a report on Thursday, July 30th. Sanford C. Bernstein reiterated a "market perform" rating and issued a $225.00 target price (up from $203.00) on shares of AbbVie in a research report on Tuesday, June 23rd. HSBC boosted their target price on AbbVie from $300.00 to $315.00 and gave the stock a "buy" rating in a research note on Thursday, September 10th. Citigroup increased their target price on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a report on Wednesday, July 15th. Finally, Piper Sandler lifted their price target on shares of AbbVie from $298.00 to $303.00 and gave the company an "overweight" rating in a report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $274.32.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women's health.

The company's products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.